IMMUNOHISTOCHEMISTRY CD19 Test
Cost: 510.0 AED
Test Components:
- Price: 510.0 AED
Sample Condition:
Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Report Delivery:
- Sample: Daily by 6 pm
- Report Block: 5 days
- Tissue Biopsy: 5 days
- Tissue large complex: 7 days
Method:
Immunohistochemistry
Test Type:
Cancer
Doctor:
Oncologist
Test Department:
HISTOLOGY
Pre Test Information:
Provide a copy of the Histopathology report, Site of biopsy and Clinical history.
Test Details:
Immunohistochemistry (IHC) is a technique used to detect specific proteins in tissue samples. CD19 is a cell surface protein that is primarily expressed on B cells. The CD19 test using immunohistochemistry involves the use of specific antibodies that bind to the CD19 protein in tissue sections.
To perform the CD19 test, tissue samples are first fixed and embedded in paraffin. Thin sections of the tissue are then cut and mounted onto glass slides. The slides are deparaffinized and rehydrated to prepare them for antibody staining.
Next, the tissue sections are treated with an antigen retrieval solution to unmask the CD19 protein and enhance antibody binding. This is followed by blocking of nonspecific binding sites using a blocking agent, such as serum or protein-based solutions.
The tissue sections are then incubated with a primary antibody specific for CD19. The primary antibody binds to the CD19 protein if it is present in the tissue sample. After washing away any unbound primary antibody, a secondary antibody is applied.
The secondary antibody is conjugated to a detection system, such as an enzyme or fluorescent dye, which allows for visualization of the CD19 protein. Finally, the tissue sections are treated with a substrate or dye that reacts with the detection system, resulting in the formation of a visible signal.
This signal can be observed under a microscope and indicates the presence of CD19 protein in the tissue sample.
The CD19 immunohistochemistry test is commonly used in the diagnosis and classification of B-cell lymphomas, leukemias, and other B-cell-related diseases. It provides valuable information about the presence and distribution of CD19-positive cells in tissue samples, aiding in the determination of disease prognosis and treatment decisions.
| Test Name | IMMUNOHISTOCHEMISTRY CD19 Test |
|---|---|
| Components | |
| Price | 510.0 AED |
| Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
| Method | Immunohistochemistry |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | HISTOLOGY |
| Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Test Details | Immunohistochemistry (IHC) is a technique used to detect specific proteins in tissue samples. CD19 is a cell surface protein that is primarily expressed on B cells. The CD19 test using immunohistochemistry involves the use of specific antibodies that bind to the CD19 protein in tissue sections. To perform the CD19 test, tissue samples are first fixed and embedded in paraffin. Thin sections of the tissue are then cut and mounted onto glass slides. The slides are deparaffinized and rehydrated to prepare them for antibody staining. Next, the tissue sections are treated with an antigen retrieval solution to unmask the CD19 protein and enhance antibody binding. This is followed by blocking of nonspecific binding sites using a blocking agent, such as serum or protein-based solutions. The tissue sections are then incubated with a primary antibody specific for CD19. The primary antibody binds to the CD19 protein if it is present in the tissue sample. After washing away any unbound primary antibody, a secondary antibody is applied. The secondary antibody is conjugated to a detection system, such as an enzyme or fluorescent dye, which allows for visualization of the CD19 protein. Finally, the tissue sections are treated with a substrate or dye that reacts with the detection system, resulting in the formation of a visible signal. This signal can be observed under a microscope and indicates the presence of CD19 protein in the tissue sample. The CD19 immunohistochemistry test is commonly used in the diagnosis and classification of B-cell lymphomas, leukemias, and other B-cell-related diseases. It provides valuable information about the presence and distribution of CD19-positive cells in tissue samples, aiding in the determination of disease prognosis and treatment decisions. |
